Phase III Study Compared Neoadjuvant Therapy With Lapatinib Or Trastuzumab For Early

[News]

Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12...

More... (http://mnt.to/f/3NWT)